Search

everythinglearnresearchcommunity

for

Search:↓

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

Treatments for hair loss, specifically discussing the use of RU58841 and Pyrilutamide from Actifolic. The poster is inquiring about experiences with these products and results.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

A 21-year-old is using Dualgen-5R (minoxidil and tretinoin) and weekly dermarolling to address hair loss, noticing some progress after three months. They plan to add an anti-androgen like RU58841 or Kx826 for better long-term results.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

RU58841 was ineffective for OP, who is considering adding KX-826 with finasteride. User8 suggests KX-826 may help when combined with minoxidil and dutasteride.

The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.

KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.

The user is considering reducing their finasteride dose from 2.5mg to 1.25mg to make the supply last longer and is concerned about potential changes in results. They have been using the 2.5mg dose for four months.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

GHK-Cu is discussed for its potential anti-aging and healing properties, with some users considering its effects on hair growth. One user mentions using Folligen Spray and topical finasteride, noting improved healing but uncertain hair growth results.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

User sshamu's progress pictures of 4 months using minoxidil foam and 1MM dermarolling for hair loss, which resulted in impressive results. There is also discussion about how often to use the treatments, as well as potential side effects of finasteride.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

A user used oral finasteride and minoxidil for hair loss, seeing new hair growth under a microscope but no visible change. Commenters debated if the growth was real hair or fibers, and the user will update every 90 days.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

Andreas Townsend's hair growth, likely due to a combination of finasteride and minoxidil treatments, as well as possibly a hair transplant. People have been discussing the efficacy of these treatments in achieving Townsend's level of hair growth.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.